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Abstract 
Gastrointestinal endoscopy has a major diagnostic and 
therapeutic role in most gastrointestinal disorders; 
however, limited information is available about clini-
cal efficacy and safety in pregnant patients. The major 
risks of endoscopy during pregnancy include potential 
harm to the fetus because of hypoxia, premature labor, 
trauma and teratogenesis. In some cases, endoscopic 
procedures may be postponed until after delivery. 
When emergency or urgent indications are present, 
endoscopic procedures may be considered with some 
precautions. United States Food and Drug Administra-
tion category B drugs may be used in low doses. Endo-
scopic procedures during pregnancy may include upper 
gastrointestinal endoscopy, percutaneous endoscopic 
gastrostomy, sigmoidoscopy, colonoscopy, enteroscopy 
of the small bowel or video capsule endoscopy, endo-
scopic retrograde cholangiopancreatography and endo-
scopic ultrasonography. All gastrointestinal endoscopic 
procedures in pregnant patients should be performed 
in hospitals by expert endoscopists and an obstetrician 
should be informed about all endoscopic procedures. 
The endoscopy and flexible sigmoidoscopy may be 
safe for the fetus and pregnant patient, and may be 
performed during pregnancy when strong indications 
are present. Colonoscopy for pregnant patients may 
be considered for strong indications during the second 
trimester. Although therapeutic endoscopic retrograde 
cholangiopancreatography may be considered during 
pregnancy, this procedure should be performed only 
for strong indications and attempts should be made to 
minimize radiation exposure. 
© 2014 Baishideng Publishing Group Inc. All rights reserved.
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Core tip: Gastrointestinal endoscopy has a major diag-
nostic and therapeutic role in most gastrointestinal dis-
orders; however, limited information is available about 
clinical efficacy and safety in pregnant patients. Endo-
scopic procedures during pregnancy may include upper 
gastrointestinal endoscopy, percutaneous endoscopic 
gastrostomy, sigmoidoscopy, colonoscopy, enteroscopy 
of the small bowel or video capsule endoscopy, endo-
scopic retrograde cholangiopancreatography and endo-
scopic ultrasonography. All gastrointestinal endoscopic 
procedures in pregnant patients should be performed 
in hospitals by expert endoscopists and an obstetrician 
should be informed about all endoscopic procedures.
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INTRODUCTION
Although gastrointestinal (GI) endoscopy is usually safe, 
the safety of  this procedure during pregnancy must be 
evaluated. The best option may be to postpone the pro-
cedure until the third trimester or postpartum. When 
therapeutic intervention is necessary in specific clinical 
situations, GI endoscopy may be a safe alternative to ra-
diography or surgical intervention. 
However, many potential risks are associated with 
endoscopy during pregnancy[1]. Over sedation may cause 
maternal hypotension, maternal hypoxia and potentially, 
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fetal hypoxia. The fetus may be exposed to potentially 
teratogenic drugs, radiation and premature birth risk[1-6]. In 
addition, the pregnant woman’s uterus may apply pressure 
to the inferior vena cava, causing decreased uterine blood 
flow and fetal hypoxia. Therefore, the American Society 
for Gastrointestinal Endoscopy has issued guidelines for 
endoscopy in pregnant women (Table 1)[2].
The purpose of  this article was to review GI endos-
copy in pregnancy including indications and treatment 
options.
FETAL SAFETY OF DRUGS USED IN 
ENDOSCOPIC PROCEDURES
To prevent hypoxia and hypotension during GI endosco-
py, pregnant patients may be positioned in the left lateral 
position and given prompt intravenous hydration with 
normal saline or other high osmolar solutions. The use 
of  analgesics and sedatives should be minimized and the 
endoscopic procedure may be terminated prematurely 
when necessary[5-6]. A major challenge for anesthesiolo-
gists is sedation in pregnant women. Inhalational or local 
anesthetic drugs have no proven teratogenic effects in 
humans; however benzodiazepines are associated with 
congenital anomalies. Any drugs that are given during 
pregnancy must be used with caution. Antidepressant 
drugs may affect the fetus because they could cross the 
placental barrier[5-7].
Endoscopic procedures are associated with terato-
genic risk in the first trimester and premature labor in 
the third trimester. Therefore, endoscopic procedures 
should be considered with caution in pregnant patients 
with anesthesiology assistance. The United States Food 
and Drug Administration (FDA) have defined five cat-
egories of  drugs in terms of  safety to pregnant women 
(Table 2)[8]. Category A drugs are considered safe during 
pregnancy and category B drugs also may be used during 
pregnancy (Table 2). Category C drugs may be used when 
required during pregnancy, but there may be risks to the 
fetus. Category D drugs usually are contraindicated dur-
ing pregnancy and are used only with extreme caution. 
Category X drugs are absolutely contraindicated during 
pregnancy (Table 2)[8].
There are no category A drugs that are used for 
endoscopy. During endoscopic procedures, category B 
and when necessary, category C drugs may be recom-
mended (Table 3). Category D drugs may be used when 
the benefits outweigh the risks. These categories are of  
limited use in determining the safety of  one-time use; 
therefore, consultation with an obstetrician about drugs 
should be considered. For most procedures, anxiolytic 
drugs or moderate sedation may be adequate. Heavy 
sedation, when necessary, should be administered by an 
anesthesiologist[2].
The opiate analgesic meperidine was commonly used 
for GI endoscopy for the general population; however, 
it has been replaced by short-acting analgesics because 
of  adverse events (respiratory depression and seizures) 
(Table 3). After intravenous administration, meperidine 
is transferred rapidly across the human placenta and is 
metabolized to normeperidine, which has a longer half-
life than meperidine. Repeated administration of  meperi-
dine at high doses may cause progressive accumulation 
of  normeperidine, maternal respiratory depression and 
maternal seizures. Meperidine is a drug in category B for 
regular use, but is category D for prolonged use at high 
doses. Meperidine use should be limited to 50-75 mg for 
endoscopic procedures in pregnant women[4,5,9]. Fentanyl 
(category C) is a potent narcotic that has a rapid onset 
of  action and a shorter recovery time than meperidine; 
fentanyl is usually safe in low doses (< 125 mg) during 
pregnancy (Table 3)[2-5].
Benzodiazepines (diazepam and midazolam) are com-
monly used before GI endoscopy to reduce anxiety, in-
duce brief  amnesia and produce muscle relaxation. Pro-
longed use of  diazepam during early pregnancy may be 
associated with cleft palate malformations; however, this 
association is unproven[10-13]. The use of  diazepam in the 
first trimester of  pregnancy, however, is not safe because 
of  a strong relation between diazepam use and mental 
retardation or neurological defects, cardiac defects and 
Mobius syndrome (a neurological disorder with normal 
intelligence but sixth and seventh nerve palsies)[11,14,15]. 
There are limited data about the use of  midazolam, but 
there is no known association of  midazolam with oral 
cleft palate. However, midazolam may be associated with 
transient depression of  neonatal neurobehavioral respon-
siveness during labor[16,17]. When meperidine cannot be 
used, the preferred benzodiazepine is midazolam (cat-
egory D) because associated fetal abnormalities have not 
been reported. 
Propofol (category B) is commonly used for anesthe-
sia during endoscopy. It is a short-acting anesthetic agent 
with a short recovery period. It is usually administered by 
anesthesiologists because of  its narrow therapeutic index 
and potential for respiratory depression. Endoscopy soci-
eties have recommended the use of  propofol for patients 
who are difficult to sedate or have complicated clinical 
situations. Propofol is considered safe during pregnancy, 
but there are insufficient data available about the use of  
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Table 1  General principles for endoscopy in pregnant 
women1
1 Always have a strong indication, particularly in high-risk pregnancies
2 Endoscopy should be postponed to second trimester whenever possible
3 Lowest effective dose of sedative medications should be used
4 Especially category A or B drugs should be used
5 Procedure time should be very short
6 To avoid vena caval or aortic compression, pregnant women should 
be positioned in the left pelvic tilt or left lateral position
7 Fetal heartbeat should be detected before sedation and also after the 
endoscopic procedure
8 Obstetric support should be available whenever pregnancy-related 
complications occur
9 Placental abruption, imminent delivery, ruptured membranes, or 
eclampsia are defined as obstetric complications of endoscopy
1Based on Qureshi et al[2] (2005).
propofol in the first trimester[4,5,18].
Ketamine (category B) can be used for endoscopy 
when there is insufficient sedation with propofol. Ket-
amine has a rapid onset of  action and a short duration 
of  effect, but data are limited about use of  ketamine 
during the first trimester of  pregnancy, prolonged use or 
overdose[19].
Naloxone (category B) is a fast-acting narcotic antag-
onist that may be administrated to reverse narcotic over-
dose during endoscopy. Naloxone crosses the placenta 
within 2 min[2,20]. It is used to treat respiratory depression, 
systemic hypotension or unresponsiveness in closely 
monitored settings during or after endoscopy. Naloxone 
is given in small, graded doses and titrated to the required 
effect during pregnancy, because there has been one 
neonatal fatality that was attributed to naloxone use[21]. 
Naloxone is contraindicated in narcotic-dependent preg-
nant patients because of  the risk of  opiate withdrawal 
syndrome[22]. Flumazenil (category C) is a benzodiazepine 
antagonist that is used to reverse over sedation from 
benzodiazepines that are administered during endoscopy. 
Its fetal risks during pregnancy are unknown and is used 
only to reverse benzodiazepine overdose. Flumazenil 
overdose may cause maternal seizures, especially when 
given to patients who are chronically habituated to ben-
zodiazepines. The risk of  benzodiazepine overdose may 
be minimized by careful and slow titration of  minimal 
doses of  benzodiazepines required for endoscopy[19-23].
UPPER GASTROINTESTINAL 
ENDOSCOPY
It would be ideal to postpone endoscopic procedures 
until after delivery; however, pregnant patients may de-
velop conditions that require urgent upper endoscopy. 
The most common indications for esophagogastroduo-
denoscopy (EGD) in pregnant patients include major 
or continued GI hemorrhage, dysphagia, and refractory 
nausea and vomiting (Table 4). The EGD procedure is 
reasonably safe for the fetus and may be performed when 
strongly indicated during pregnancy. 
In a multicenter retrospective study of  83 pregnant 
women concerning the safety and clinical efficacy of  
EGD in pregnant patients, indications for endoscopy in-
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Table 2  United States food and drug administration categorization of drug safety during pregnancy1
Category Risk Description
A No risk has been shown in 
controlled studies 
Sufficient, well-controlled studies have not demonstrated a risk to the fetus in any trimester of pregnancy
B No risk in humans Sufficient, well-controlled studies have not demonstrated an increased risk of fetal abnormalities despite adverse 
findings in animals or, in the absence of adequate human studies, animal studies show no fetal risk. The chance of 
fetal harm is very low but still is a possibility
C Risk cannot be ruled out Sufficient, no well-controlled human studies, where animal studies have shown a risk to the fetus. There is a chance 
of fetal harm if the drug is administered during pregnancy, but the potential benefits should be considered and may 
outweigh the potential risk
D Positive evidence of risk Studies in humans, or investigational or postmarketing data, have demonstrated fetal risk. Nevertheless, poten-
tial benefits from the use of the drug may outweigh the potential risk. For example, the drug may be acceptable if 
needed in a life-threatening situation or for serious disease for which safer drugs cannot be used or are ineffective
X Contraindicated in 
pregnancy
Studies in animals or humans (investigational or postmarketing reports) have demonstrated positive evidence of 
fetal abnormalities or risk that clearly outweighs any possible benefit to the patient
1Adapted from Food and Drug Administration (1980)[8].  
Table 3  Safety of anesthetics commonly used in gastrointestinal endoscopy
Drug FDA category in 
pregnancy
Key points about drug safety
Narcotics
   Meperidine B, but D at term Repeated use of high dose and prolonged administration can cause respiratory depression and seizures
   Fentanyl C It is safe in low doses
   Propofol B Generally suggested for use in patients who are sedated with difficulty and in complicated clinical situations
General anesthetics
   Ketamine B Data are limited with humans; animal data suggest prolonged use is not safe
Sedatives
   Diazepam D Some congenital malformations and mental retardation may be associated with diazepam, the use of diazepam 
during pregnancy is restricted
   Midazolam D As a benzodiazepine member, its use is restricted during pregnancy, especially in the first trimester
Reversing agents
   Naloxone B It probably is safe but should be used only in respiratory depression, systemic hypotension, or unresponsiveness 
in a closely monitored pregnant woman after endoscopy
   Flumazenil C Fetal risks are unknown, but it should be given carefully in small doses
FDA: United States Food and Drug Administration.
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women had lower frequencies of  blood transfusion, 
hypovolemic shock or EGD than nonpregnant women. 
The proportion of  EGD procedures that led to thera-
peutic intervention was similar for pregnant (8.9%) and 
nonpregnant women (7.2%). The frequency of  maternal 
mortality and fetal loss were < 1% and it was concluded 
that it was appropriate to defer endoscopy in most pa-
tients who were hemodynamically stable and who had 
self-limited NVUGB[29].
Patients who have cirrhosis are not likely to become 
pregnant because they may have hypothalamic-pituitary 
dysfunction and associated disturbance of  estrogen and 
endocrine metabolism. The exact incidence of  pregnancy 
in cirrhosis is not known, but only 45 cases of  cirrhosis 
occur in every 100000 women of  reproductive age. On 
the other hand, women with noncirrhotic portal hyperten-
sion have normal frequency of  fertility and these patients 
may have 45% incidence of  variceal bleeding during 
pregnancy and 18%-50% associated mortality. The vari-
ceal bleeding typically occurs during the second or third 
trimester. The high severity of  variceal bleeding in preg-
nancy may be attributed to increased fluid retention and 
cardiac output in pregnancy. Women who have esophageal 
varices or severe liver disease should be advised about the 
high risk of  variceal bleeding and hepatic decompensation 
during pregnancy. Nonselective β-blockers may be given 
to patients who have esophageal varices or severe liver dis-
ease, but the safety of  β-blockers is controversial because 
of  reports of  premature labor, fetal growth restriction, 
neonatal apnea, bradycardia and hypoglycemia. Further-
more, myometrial relaxation of  the gravid uterus is a β2-
receptor-mediated process and nonselective β-blockers, 
such as propranolol, may counteract the effect of  β2-
receptor stimulation. The pregnant patient should be in-
formed about the possible benefits and adverse effects of  
β-blockers during pregnancy. 
THERAPEUTIC ENDOSCOPY
Endoscopic hemostatic techniques for nonvariceal bleed-
ing include injection therapy (epinephrine, sclerosing 
agents, thrombin or cyanoacrylate), ablative therapy (elec-
trocoagulation, thermocoagulation, photocoagulation or 
argon plasma coagulation), and compression (hemoclips, 
detachable snares, graspers or sutures)[30]. Although there 
are numerous techniques, there are few case reports about 
the fetal safety of  endoscopic hemostasis for NVUGB, 
including epinephrine injection, thermocoagulation or 
electrocoagulation. In the available reports, hemostatic 
techniques were successful in all patients except for one 
patient who required surgery. The fetal outcomes were all 
healthy infants without any fetal malformations[24,27,30,31].
Epinephrine (category C) may cause a decrease in 
uterine blood flow. Although there are limited data from 
case reports, no adverse events from epinephrine injec-
tion have been reported and the benefits (cessation of  
hemorrhage and prevention of  rebleeding) may outweigh 
the risks[1,2,26,32]. Electrocautery is safe when used for he-
mostasis, but amniotic fluid may conduct electrical cur-
cluded GI bleeding, abdominal pain and vomiting[24]. The 
most common causes of  the GI bleeding were Mallory-
Weiss tear and peptic ulcer, which were significantly lower 
than the reported frequencies in non-pregnant patients 
The diagnostic yield for upper GI bleeding was 95% and 
there were no patients who had premature labor or con-
genital fetal malformation. 
During pregnancy, increased progesterone and estro-
gen levels mediate lower esophageal sphincter relaxation, 
with 50% decreased lower esophageal sphincter pressure 
during, compared with before, pregnancy and decreased 
gastric emptying that may cause symptoms of  gastro-
esophageal reflux disease (GERD). As pregnancy pro-
gresses, the frequency and intensity of  GERD symptoms 
may increase because of  changes in GI motility during 
pregnancy and the physical effects of  the gravid uter-
us[25,26]. The EGD procedure is rarely helpful or indicated 
for nausea or vomiting during pregnancy or hyperemesis 
gravidarum. In patients who have major upper GI bleed-
ing, severe nausea and vomiting accompanied by abdomi-
nal pain that is refractory to medical treatment or signs 
of  gastroduodenal obstruction, EGD may be appropriate 
for diagnosis of  major peptic ulcers, diagnosis of  gastric 
outlet obstruction or treatment of  a bleeding site. Debby 
et al[27] reported a study of  patients who had EGD in the 
first trimester of  pregnancy, in that study, 49 patients had 
intractable nausea with or without epigastric pain and 11 
patients had nausea and upper GI bleeding; the diagnos-
tic yield of  EGD was similar for patients who had GI 
bleeding or intractable vomiting. The endoscopic findings 
changed the treatment of  patients who had nausea and 
vomiting minimally, and they concluded that EGD may 
be useful for treatment of  upper GI bleeding, but not 
nausea, vomiting or hyperemesis gravidarum[27].
Acute nonvariceal upper GI bleeding (NVUGB) is 
a common clinical emergency that causes 50-160 hospi-
talizations per 100000 adults annually. Mortality may be 
decreasing but remains at 10%-14%[28]. Endoscopy for 
NVUGB may provide an assessment of  the risk of  re-
bleeding and enable therapeutic hemostasis that could re-
duce bleeding, frequency of  surgery and risk of  death. In 
a population-based study of  NVUGB, there were 1210 
pregnant women and 6050 nonpregnant women who had 
NVUGB. The most common causes of  NVUGB were 
Mallory-Weiss tear in pregnant women and peptic ulcer 
disease and gastritis in nonpregnant women[29]. Pregnant 
Table 4  Indications for endoscopy in pregnancy 
No. Indication
1 Major or continued bleeding
2 Severe or refractory nausea and vomiting or abdominal pain
3 Dysphagia or odynophagia
4 High suspicion of colonic mass
5 Severe diarrhea with negative evaluation
6 Biliary pancreatitis, CBD stones, or cholangitis
7 Biliary or pancreatic ductal injury
Based on American Society for Gastrointestinal Endoscopy. 
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rent to the fetus; therefore, during electrocoagulation, a 
grounding pad should be placed such that the uterus is 
not between the electrical cord and the grounding pad, 
and bipolar electrocautery should be used to minimize 
the risk of  stray current going through the fetus. 
There are limited data about hemostasis for nonvari-
ceal bleeding in pregnant patients, and the therapeutic 
technique is chosen from expert opinion that is based on 
results of  clinical studies in nonpregnant patients. Pro-
phylactic or urgent endoscopic injection sclerotherapy 
(EIS) and endoscopic band ligation (EBL) are safe pro-
cedures during pregnancy. When bleeding is not stopped 
endoscopically in cirrhotic patients, an emergency tran-
sjugular intrahepatic portosystemic shunt (TIPSS) is 
indicated, but data about pregnant cirrhotic women are 
limited[33-39]. There are only a few case reports about the 
treatment options for esophageal varices, and further 
studies are needed about the treatment of  hemorrhage 
during pregnancy. In the early 1980s, EIS was a first-
line treatment procedure for bleeding esophageal varices. 
However, only a few cases of  EIS with sclerosing agents 
(polidocanol, absolute alcohol or sodium tetradecyl sul-
fate) have been reported during pregnancy[36-39]. There are 
no studies available about the effects of  these sclerosing 
agents on the fetus; however, the procedure is considered 
safe and effective in controlling active variceal bleeding. 
Vasoactive drugs that are used to achieve hemostasis are 
contraindicated during pregnancy because these drugs 
(vasopressin and terlipressin) may induce labor or fetal 
malformations.
EBL may be an effective treatment option for active 
variceal hemorrhage and prophylaxis for this severe com-
plication during pregnancy. There are several case reports 
that describe successful hemostasis without fetal compli-
cations[40-41]. When EBL is used, there is no risk of  migra-
tion of  a toxic substance to the placenta. Studies of  EBL 
vs EIS in nonpregnant patients have shown improved 
reduction in rebleeding and mortality with EBL[40,42]. 
However, there are no studies that directly compare EBL 
to EIS in pregnant patients. 
In a previous study, 17 patients had acute variceal 
bleeding during pregnancy because of  noncirrhotic portal 
hypertension that was caused by extrahepatic portal vein 
obstruction or portal fibrosis. These patients underwent 
EIS with either absolute alcohol or sodium tetradecyl 
sulfate[43]. There were two patients who required EBL 
after failure of  EIS to obliterate esophageal varices[43]. 
In an another report, 10 patients underwent EIS with 
absolute alcohol for treatment of  active variceal bleeding 
(five patients) or prophylaxis against variceal bleeding (five 
patients). Hemostasis was achieved in the five patients 
who had active variceal bleeding and all 10 patients de-
livered healthy infants[44]. In pregnant patients, EBL may 
be a reasonable option for the treatment of  acute variceal 
bleeding and prophylaxis against variceal bleeding. EIS 
may be a secondary choice for acute variceal bleeding be-
cause of  probable detrimental effects on fetal safety. 
When endoscopic and pharmacologic therapy fail, 
TIPSS may be a salvage procedure for pregnant women 
who have variceal bleeding that is recurrent, difficult to 
treat or unresponsive to endoscopic or pharmacologic 
treatment. However, adequate controlled trials are lack-
ing, and this procedure should be limited to a selected 
group of  patients. TIPSS placement is associated with 
radiation exposure to the patient and fetus because the 
procedure usually requires prolonged fluoroscopy. There 
are several reported cases of  TIPSS placement in preg-
nancy in which the fetal dose of  radiation was 5.2 mSv to 
2.1 mGy[35,45,46].
The average person in the United States receives 
0.0036 Sv (0.36 rem) ionizing radiation annually, includ-
ing 0.0006 Sv (0.06 rem) from manmade sources, such 
as diagnostic radiography. Fetal radiation exposure may 
cause developmental abnormalities, especially when the 
exposure occurs during the first trimester. Fetal radiation 
exposure should not exceed 0.001 Sv (0.1 rem) during the 
first trimester and later exposures > 0.001 Sv (0.1 rem) 
during neuron development and migration may be asso-
ciated with microcephaly, seizures, decline in mental abil-
ity and childhood cancer. The maximum permitted dose 
of  ionizing radiation to the fetus during the entire preg-
nancy is 0.005 Sv (0.5 rem)[47-49]. Therefore, in patients 
who have upper GI bleeding all therapeutic procedures 
that are used in nonpregnant patients can also be used in 
pregnant patients. In cirrhotic patients, pregnancy is not 
an absolute contraindication for TIPSS placement for the 
treatment of  relapsing bleeding varices, but minimizing 
the duration of  radiation exposure is important to pre-
vent toxic radiation exposure to the fetus. 
PERCUTANEOUS ENDOSCOPIC 
GASTROSTOMY 
During pregnancy, optimal nutrition is important to 
minimize maternal and neonatal morbidity[50,51]. Nausea 
and vomiting are observed in 80% pregnancies but are 
usually mild and self-limited. Patients who have severe 
hyperemesis gravidarum with dehydration and ketonuria 
should be hospitalized and treated with intravenous hy-
dration and antiemetic drugs. When the hospitalization is 
prolonged and there is no oral intake, supportive nutri-
tion with enteral feeding or total parenteral nutrition may 
be considered. Long-term nasogastric feeding is limited 
by patient intolerance and nasal septal necrosis. Adverse 
events may limit the use of  long-term total parental nutri-
tion during pregnancy[52].
Percutaneous endoscopic gastrostomy (PEG) is an 
important option for long-term enteral feeding. Place-
ment of  PEG tubes in pregnant women may be limited 
because of  risks of  uterine damage, fetal injury, prema-
ture labor and infection, but there were no major com-
plications associated with PEG tube placement in several 
reported cases[53-60]. In previous studies, PEG enteral 
nutritional support was provided for an average 14 wk. 
During pregnancy, PEG tube placement is feasible for 
optimal enteral nutrition in the critical care setting and in 
the third trimester of  pregnancy. A major risk of  PEG 
Savas N. Endoscopy in pregnancy
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during pregnancy is puncture of  the uterus or fetus dur-
ing transabdominal needle insertion, but this risk may 
be minimized by demarcating the upper border of  the 
uterus before PEG and inserting the PEG needle ≥ 5 
cm cephalad. 
Placement of  a PEG tube is reserved for severe re-
fractory cases of  impaired nutrition of  the mother and 
fetus. The pregnant woman should be informed about 
the risks of  the procedure and potential placental injury. 
If  possible, less invasive alternative techniques, such as a 
nasoenteric feeding tube or peripherally inserted catheter 
for parenteral nutrition, should be considered, and PEG 
tube placement may be offered when other methods are 
unsuccessful or declined by the patient. When refractory 
nausea and vomiting persist despite PEG tube placement, 
and the risk of  aspiration pneumonia is increased, the 
PEG may be converted to a percutaneous endoscopic 
gastrojejunostomy[50,61].
SIGMOIDOSCOPY
Most pregnant patients are young, healthy women and 
the gestational period is 40 wk. Therefore, most patients 
do not need to have flexible sigmoidoscopy or colonos-
copy during pregnancy. Lower GI endoscopy is avoided 
for weak indications during pregnancy and deferred 
until after the first trimester or postpartum[62]. However, 
sigmoidoscopy or colonoscopy is indicated for the evalu-
ation of  major lower GI bleeding, suspicion of  colonic 
mass or severe diarrhea.
Sigmoidoscopy is usually safe during pregnancy and 
indications include rectal bleeding, chronic diarrhea, 
abdominal pain and rectal pain. Guidelines for colonos-
copy during pregnancy are limited because of  insuffi-
cient data, but colonoscopy is typically safe and effective 
when obstetrical consultation and close monitoring are 
performed[63,64].
The safety and efficacy of  flexible sigmoidoscopy 
during pregnancy was studied in a case controlled 
study of  45 patients undergoing sigmoidoscopy[65]. In 
that study, the most common clinical indication was 
hematochezia in 29 patients, diarrhea in 10 patients 
and abdominal pain in 4 patients. The most common 
sigmoidoscopic diagnoses were reactivated or newly di-
agnosed inflammatory bowel disease, bleeding internal 
hemorrhoids and other types of  colitis. In 29 patients 
who had hematochezia, 8 patients had de novo or recur-
rent episodes of  ulcerative colitis, 7 patients had de novo 
or recurrent episodes of  Crohns disease, 3 patients had 
proctosigmoiditis, 2 patients had bleeding internal hem-
orrhoids, 1 patient had pseudomembraneous colitis and 
1 patient had a sigmoid colon adenoma. Hematochezia 
gave the highest diagnostic yield compared with other 
clinical indications. Therapeutic changes because of  the 
sigmoidoscopic findings occurred in 24 patients, includ-
ing changing or starting drugs for inflammatory bowel 
disease in 15 patients, steroid enemas for nonspecific 
proctitis in 2 patients, avoiding surgery in 2 patients and 
treatment of  hemorrhoids in 2 patients.
Other studies of  sigmoidoscopy performed dur-
ing pregnancy have included case reports and a mailed 
survey[26,66-70]. Multiple case reports describing flexible 
sigmoidoscopy in pregnant patients have confirmed the 
safety of  this procedure. These studies suggested that 
sigmoidoscopy during pregnancy may not induce labor or 
cause congenital malformations. Thus, sigmoidoscopy is 
not contraindicated and may be considered in medically 
stable patients who have important indications. Sigmoid-
oscopy should be performed with maternal monitoring 
(electrocardiography and pulse oximetry) after obstetric 
consultation and after medical stabilization. Medical 
stabilization may include blood transfusion and supple-
mental oxygen[62,64]. For evaluation of  a change in bowel 
habits, abdominal pain, family history of  colon cancer or 
routine screening or surveillance, sigmoidoscopy is not 
recommended during pregnancy but is deferred until > 6 
wk postpartum[63,64].
COLONOSCOPY
There are insufficient data about the safety of  perform-
ing a colonoscopy during pregnancy. The largest case 
control study about colonoscopy in pregnancy included 
20 patients who were evaluated for symptoms including 
hematochezia, diarrhea, bloody diarrhea and abdominal 
pain[71]. In that study, colonoscopy was performed in 16 
patients in the second trimester and in 4 patients in the 
first or third trimester; colonoscopic diagnoses included 
ulcerative colitis, Crohn disease, ischemic colitis and 
lymphocytic colitis. Colonoscopy resulted in a change in 
therapy in seven (35%) patients. Most patients had favor-
able fetal outcomes (18 healthy infants) and there was 
one involuntary abortion and one infant who was born 
with a cardiac defect (septum secundum)[71].
In another study of  eight pregnant women who had 
colonoscopy (10 different medical centers) there were 
6 healthy infants born, 1 elective abortion and one fetal 
death that was unrelated to colonoscopy[65]. Outcomes 
were independent of  the trimester during which colo-
noscopy was performed. In addition, several case reports 
about colonoscopy during pregnancy have shown 8 
healthy births, 2 stillbirths unrelated to colonoscopy and 
1 unknown fetal outcome[72-80].
With limited data about safety and adverse events, 
colonoscopy should be limited to patients who have 
strong indications or life-threatening emergencies dur-
ing the second trimester. However, colonoscopy may be 
considered in lieu of  surgery during the first and third 
trimester for evaluation of  suspected colon cancer, co-
lonic mass, uncontrolled severe colonic hemorrhage, 
colonic stricture of  unknown cause or colonic pseudo-
obstruction. When required before urgent colonic sur-
gery, colonoscopy should be considered, even in the first 
and third trimester. Otherwise, colonoscopy for elective 
indications, such as surveillance for prior history of  colon 
cancer or colonic polyps usually is deferred in any trimes-
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ter until after delivery. 
When colonoscopy is performed, especially in late 
pregnancy, patients should not be placed in the decubitus 
or prone position. External abdominal pressure should 
be avoided and when required, applied pressure should 
be minimal and directed away from the uterus. Limited 
information is available about the safety of  bowel cleans-
ing agents during pregnancy. The systemic absorption of  
polyethylene glycol is minimal and abdominal bloating 
and gas symptoms are less common with polyethylene 
glycol than with other laxatives[81]. However, polyethylene 
glycol solutions (category C) have not been studied dur-
ing pregnancy. Sodium phosphate solutions (category C) 
may cause fluid and electrolyte disturbance, and should 
be avoided during pregnancy. In addition, newborns may 
have bone demineralization and bone growth failure be-
cause of  maternal phosphate overload[82], but one-time 
use in pregnancy may not be detrimental. Furthermore, 
sodium phosphate preparations may be associated with 
the risk of  phosphate nephropathy[83]. Bowel preparation 
with phosphate enemas before flexible sigmoidoscopy 
may be safe, but has not been studied in pregnancy. Un-
derprepared sigmoidoscopy is generally not recommend-
ed because of  the risk of  overlooking lesions; instead, 
sigmoidoscopy with tap water enemas may be sufficient. 
Therefore, flexible sigmoidoscopy with tap water en-
emas is preferred instead of  colonoscopy. However, in 
patients who have strong indications or life-threatening 
emergencies or when the alternative treatment is surgical 
decompression, colonoscopy may be considered, even 
during the first and third trimesters.
THERAPEUTIC COLONOSCOPY
Therapeutic colonoscopy is applied for the manage-
ment of  lower GI bleeding, colonoscopic polypectomy 
and colonic stenting. All the hemostatic techniques that 
are mentioned above for upper GI bleeding can be ap-
plied during lower GI bleeding. These are mainly injec-
tion therapies, ablative therapies, hemoclips, detachable 
snares, graspers, or sutures[30]. Epinephrine is commonly 
used to treat GI bleeding and may cause hemostasis by 
vasoconstriction. Numerous studies have confirmed the 
fetal safety of  epinephrine administration during labor, 
and epinephrine is commonly added to spinal epidural 
anesthesia. A previous study showed no congenital defect 
in 35 infants who had first trimester in utero exposure 
to epinephrine[10]. However, the dosage of  epinephrine 
(category C) during pregnancy is kept low because of  
α-adrenergic effects and decreased uterine blood flow. 
Electrocautery may provide hemostasis during lower 
GI bleeding and is used during polypectomy or biopsy. 
Electrocautery of  lesions may be required, in which case 
bipolar electrocautery should be used. Removal of  non-
bleeding polyps may be postponed until after delivery[4,5,62].
Colonic tattooing is performed with India ink or 
methylene blue in nonpregnant patients, and India ink 
may persist for the entire life of  the patient. A literature 
search showed no reports of  long-term complications 
of  India ink tattooing. Although methylene blue tattoo-
ing during pregnancy has not been studied, there are 
reports of  methylene blue examination during amnio-
centesis and in the detection of  ruptured membranes. In 
these reports, fetal death and jejunal atresia were report-
ed and methylene blue has been labeled as teratogenic. 
Although the safety of  colonic injection with methylene 
blue has not been studied, its use should be avoided dur-
ing pregnancy[62,84,85].
ENTEROSCOPY AND VIDEO CAPSULE 
ENDOSCOPY
Enteroscopy of  the small bowel is a procedure with long 
duration and anesthesia time. There are no case reports 
of  enteroscopy during pregnancy and the safety of  enter-
oscopy to the fetus is unknown.
Video capsule endoscopy (VCE) is a major advance 
in the investigation of  small bowel diseases. The main 
indications include obscure GI hemorrhage, Crohn’s 
disease, celiac disease, small bowel tumors and polyposis 
syndromes. The main contraindications include known 
or suspected GI obstruction, strictures, fistulas, cardiac 
pacemakers and swallowing disorders[86]. During pregnan-
cy, the growing gravid uterus pushes and compresses the 
GI tract, and GI motility decreases because of  inhibition 
of  the intestinal smooth muscle by gestational progestin. 
These effects raise concerns about capsule impaction 
during VCE in pregnant women[87]. According to the 
United States FDA, pregnancy is a relative contraindica-
tion for VCE.
There is a report of  VCE use in a young, acutely 
bleeding pregnant patient in whom endoscopy and colo-
noscopy showed no lesion except fresh blood exiting 
the terminal ileum. On VCE, an actively bleeding jejunal 
lesion was shown and pathological examination showed 
that this lesion was a jejunal carcinoid tumor. After the 
procedure the pregnant patient and fetus did well[88]. 
Therefore, VCE may be considered during pregnancy for 
strong indications, and it is not absolutely contraindicated 
during pregnancy. 
ENDOSCOPIC RETROGRADE 
CHOLANGIOPANCREATOGRAPHY
Pregnancy is associated with an increased risk of  gall-
stone formation. Complications of  cholelithiasis, such as 
cholecystitis, common bile duct (CBD) stones and pan-
creatitis are uncommon, and are frequently treated non-
operatively. However, patients may develop complications 
of  gallstones that require intervention during pregnancy, 
and these complications are among the most frequent in-
dications for nonobstetric surgery during pregnancy[89-93].
There is controversy about the safety of  endoscopic 
retrograde cholangiopancreatography (ERCP) during 
pregnancy, and data are limited. Major concerns are asso-
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ciated with radiation exposure to the fetus and the risk of  
the procedure on the outcome of  pregnancy. In women 
who have an acute biliary tract disorder during pregnancy, 
it is advisable to provide nonoperative treatment whenev-
er possible and delay surgery until after pregnancy or the 
second trimester, when the surgical risks of  pregnancy 
are lowest. There are numerous reports about ERCP dur-
ing pregnancy, especially during the past 10 years. The 
largest series included 65 pregnant patients, and the most 
common indications for ERCP during pregnancy were 
recurrent biliary colic, abnormal liver function tests and 
a dilated bile duct on ultrasonography[94]. There were 68 
ERCP procedures performed in 65 pregnant patients 
(trimester: first, 17 patients; second, 20 patients; third, 
31 patients). The median fluoroscopy time was 1.45 min 
and most patients had a therapeutic procedure. Pancre-
atitis after ERCP developed in 11 patients (16%), but no 
patient had a severe course. Most patients achieved term 
pregnancy (89%); only 5 babies (8%) were born prema-
turely or with low birth weight, and there were no con-
genital malformations[94].
In another series of  23 patients who had ERCP (ther-
apeutic, 20 patients; diagnostic, 3 patients), complications 
included pancreatitis after ERCP (1 patient), spontaneous 
abortion (1 patient) and neonatal death at 26 h after de-
livery (1 patient)[95]. The neonatal death and post-ERCP 
pancreatitis occurred in the same patient who had three 
ERCP procedures (2 during the first trimester; 1 dur-
ing the third trimester) with pancreatic duct stenting for 
treatment of  pancreatic orifice stenosis after a previous 
surgical sphincteroplasty. 
In a study of  18 pregnant women who had biliary 
sphincterotomy for CBD stones during pregnancy (tri-
mester: first, 4 patients; second, 6 patients; third, 8 pa-
tients), short-term complications occurred in 2 patients 
(postsphincterotomy bleeding, 1 patient; mild post-ERCP 
pancreatitis and preterm labor, 1 patient); however, no 
long-term maternal complications were observed after 
a median of  6 years (range, 1-11 year)[96]. In 11 families 
that were contacted retrospectively, all 11 children were 
healthy at a mean of  6 years postpartum[96].
In a prospective study of  therapeutic ERCP during 
pregnancy, a single 10-French stent was placed without 
sphincterotomy and all patients had uncomplicated preg-
nancy and delivery of  healthy infants[97]. All women had 
ERCP with sphincterotomy and stent extraction postpar-
tum: eight patients had stones extracted. In two patients, 
the 10-French stent remained in place for 7 to 8 mo and 
no patient developed cholangitis[97].
During ERCP, radiation exposure to the fetus may in-
crease the risk of  intrauterine fetal death, malformations, 
disturbance of  growth and development, mutations and 
cancer. Therefore, these risks should be discussed with 
the pregnant patient and her family before ERCP. Lead 
shielding should be used to minimize radiation exposure 
to the uterus. When the radiation source is underneath 
the patient, the lead apron shield must be placed un-
derneath the patient and not draped over the abdomen. 
External shielding may not completely eliminate fetal 
exposure because of  internally scattered radiation, and 
efforts should be made to avoid performing ERCP dur-
ing the first trimester. Although the harmful effects of  
radiation exposure are unlikely to develop below a thresh-
old radiation dose, the threshold associated with the risk 
of  childhood cancers, such as leukemia, is unknown and 
no long-term studies (10-20 years after exposure during 
pregnancy) are available.
The use of  ERCP without fluoroscopy has been 
reported, including a 2-step procedure with (1) biliary 
sphincterotomy and stenting without fluoroscopy and (2) 
definitive ERCP with stone extraction after delivery[98,99]. 
In this study, initial CBD cannulation was performed 
with a double lumen sphincterotome; deep cannulation 
was achieved and bile was aspirated to confirm CBD 
position[98]. After deep CBD cannulation, the guide wire 
was passed and complete biliary sphincterotomy was 
performed over the guide wire. When deep CBD cannu-
lation was not possible, the sphincterotome was removed 
and needle knife sphincterotome was used. After the 
biliary orifice was identified, a complete biliary sphincter-
otomy was performed using a double lumen sphinctero-
tome. A 7-French double pigtail stent was placed in the 
CBD. After delivery the stent was removed and definitive 
ERCP was performed[98].
In another study of  ERCP without fluoroscopy, the 
procedure included cannulation of  the bile duct and 
sphincterotomy[99]. The endoscopist controlled the wire-
guided cannulation, and the cannula was not advanced 
into the duct unless the endoscopist was confident that 
the CBD had been cannulated (as assessed by the pres-
ence of  bile flowing around the wire from the papillary 
orifice). After biliary cannulation was confirmed, a wire-
guided biliary sphincterotomy was performed using a 
papillotome. When bile was not observed flowing around 
the guide wire, the catheter was not advanced to aspirate 
fluid, but a 5-French stent was inserted over the wire and 
drainage from the stent was observed. The color of  the 
draining fluid was used to assess whether the stent was in 
the bile or pancreatic duct. When the stent showed bile 
flow, a stent-guided biliary sphincterotomy using a needle 
knife was performed. The stent was removed after biliary 
sphincterotomy[99].
Although these techniques may be less risky for the 
pregnant woman and fetus, ERCP should be avoided for 
weak indications, such as preoperative cholangiography in 
patients who have low probability of  having CBD stones. 
All women of  childbearing age should be asked about 
the possibility of  pregnancy and a pregnancy test should 
be ordered based on clinical history. Other methods of  
diagnosis without radiation exposure should be consid-
ered. Magnetic resonance cholangiopancreatography may 
provide diagnostic information for various hepatobiliary 
conditions, and endoscopic ultrasonography is highly 
sensitive and specific for CBD stones. However, ERCP 
with or without fluoroscopy is indicated in patients who 
have CBD stones, biliary pancreatitis, cholangitis and bile 
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duct dilation on abdominal ultrasonography with known 
gallstones and abnormal liver function tests. 
ENDOSCOPIC ULTRASONOGRAPHY
Endoscopic ultrasonography is commonly performed 
for the diagnosis of  GI and pancreatobiliary diseases. 
Endoscopic ultrasonography may reduce unnecessary 
interventions in patients who have a low or moderate 
probability of  developing CBD stones and it is a safe 
alternative to fluoroscopy for the evaluation of  biliary 
disorders during pregnancy. Case reports about the use 
of  endoscopic ultrasonography for pregnant patients are 
available. The largest study included endoscopic ultra-
sonography performed in six pregnant patients for sus-
pected CBD stones[99] Endoscopic ultrasonography find-
ings in this study included CBD stones (two patients), 
biliary sludge (two patients) and nonspecific findings (two 
patients). All six patients had ERCP after endoscopic 
ultrasonography and there were no maternal complica-
tions; fetal outcome was favorable for five infants and 
unknown for one infant[99].
In another report, endoscopic ultrasonography was 
performed for acute pancreatitis of  unknown cause 
in three pregnant patients. Biliary pancreatitis without 
CBD stones was observed in two patients and pancre-
atitis caused by an unspecified pancreatic anomaly was 
observed in one pregnant patient. There were no re-
ported maternal complications and two healthy infants 
were delivered; however, there was one fetal death be-
cause of  recurrent cholangitis at 10 wk after endoscopic 
ultrasonography[100].
Endoscopic ultrasonography may prolong the evalu-
ation. However, when endoscopic ultrasonography is 
normal, ERCP intervention may be avoided. In addi-
tion, endoscopic ultrasonography may provide other 
useful information, and the added time for endoscopic 
ultrasonography may be only several minutes. Further 
studies are required to evaluate the potential benefits of  
endoscopic ultrasonography in the treatment of  pregnant 
patients. It may be acceptable to perform endoscopic 
ultrasonography when CBD stones are suspected, the 
diagnosis is unproven and magnetic resonance cholangio-
pancreatography is an undesirable alternative. 
CONCLUSION
All GI endoscopic procedures in pregnant patients 
should be performed in hospitals by expert endoscopists, 
and an obstetrician should be informed about all endo-
scopic procedures. GI endoscopy may be performed 
safely in pregnant patients when there are strong indi-
cations. To minimize fetal risks from drugs during en-
doscopy, category D drugs should be avoided, drug use 
should be minimized and an anesthesiologist should at-
tend at endoscopy. The EGD and flexible sigmoidoscopy 
may be safe for the fetus and pregnant patient and may 
be performed during pregnancy when strong indications 
are present. Colonoscopy for pregnant patients may be 
considered for strong indications during the second tri-
mester. Although therapeutic ERCP may be considered 
during pregnancy, this procedure should be performed 
only for strong indications and attempts should be made 
to minimize radiation exposure. 
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